# Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

> **NCT06529406** · PHASE4 · RECRUITING · sponsor: **University of Colorado, Denver** · enrollment: 100 (estimated)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **DRUG:** Ozanimod

## Key facts

- **NCT ID:** NCT06529406
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-29
- **Primary completion:** 2028-08-01
- **Final completion:** 2029-08-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06529406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06529406, "Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06529406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*